With its largest-ever acquisition, Angelini gains 24-year-old Catalyst, which was listed on the Nasdaq in 2006. Catalyst ...

After a surprise rejection at the beginning of 2026, the FDA has agreed to reconsider a T-cell therapy based on the same ...

With President Donald Trump recently signing an executive order to accelerate research and ease the restrictions on ...

Insulet has always been a strong leader in the medtech industry when it comes to its marketing game—and the diabetes device maker isn’t looking to rest on its laurels.  | Insulet has always been a ...

Alnylam with an untitled letter over the consumer website for Amvuttra, accusing the biotech | The FDA has hit Alnylam with ...

Since it was established nearly a year ago by the FDA, the Commissioner’s National Priority Voucher (CNPV) program has been ...

Following a series of “most favored nation” (MFN) pricing deals with 17 large pharma companies, the Trump administration ...

With commitments to invest more than $50 billion in building up its U.S. manufacturing presence, Eli Lilly has earmarked an ...

In France, Wegovy is prescribed as a second-line treatment for obesity, not for people with a lower body mass index (BMI) or ...

In the latest update to COVID and vaccine-related discourse bubbling up at the FDA, agency officials have recently blocked ...

In a bid to better deploy its boots-on-the-ground resources, the FDA is pulling back the curtain on a new pilot program, under which the regulator is leveraging “one-day inspectional assessments” to ...

Sanofi is supercharging its artificial intelligence capabilities. | Sanofi is supercharging its artificial intelligence ...